Acadia Pharmaceuticals' schizophrenia drug candidate, pimavanserin, failed to meet primary endpoint in Phase 3 study, leading to no further trials and stock decline.

Acadia Pharmaceuticals' stock fell after their schizophrenia drug candidate, pimavanserin, failed to meet the primary endpoint in a Phase 3 study. The study aimed to evaluate pimavanserin for treatment of negative symptoms of schizophrenia, but did not demonstrate a statistically significant improvement over placebo. As a result, the company announced it will not conduct any further clinical trials with pimavanserin.

March 11, 2024
9 Articles